Ventrus Biosciences Pops 20% on Positive Phase 3 Trial

Shares of Ventrus Biosciences

are seeing much strength during Monday's trading session after the company reported positive phase 3 data. The company reported positive results from its Phase 3, randomized, double-blind, placebo-controlled clinical trial of diltiazem hydrochloride cream (VEN 307) in patients with anal fissures. Ventrus' development partner, S.L.A. Pharma, has completed most of the outputs for the statistical analysis plan of the Phase 3 trial, and Ventrus is pleased to communicate the data that they have generated. The Phase 3 study randomized 465 subjects to diltiazem hydrochloride 4% or 2% w/w cream, or placebo, applied topically three times daily (TID) for 8 weeks, followed by a 4 week blinded observation period. Currently, shares of Ventrus Biosciences are trading up over 20% at $13.40 per share.